doi:10.3969/j.issn.1674-490X.2018.05.003

Abstract

Abstract: Chromatin remodeling factor 1(Rsf-1), also known as hepatitis BX-antigen associated protein(HBXAP), is overexpressed in common malignant tumors such as gastric, liver and colon cancer, and its overexpression is associated with the proliferation and malignancy grade of malignant cells. The patients with high Rsf-1 expression tend to have higher TNM stage and poorer prognosis.

Key words: Rsf-1, malignant tumor, drug resistance, cell proliferation, invasiveness

CLC Number:

References

[1] REN J, CHEN Q C, JIN F, et al. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer[J]. International Journal of Clinical and Experimental Pathology, 2014, 7(9): 5595-5608.
[2] MAO T L, HSU C Y, YEN M J, et al. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma[J]. Human Pathology, 2006,37(9):1169-1175.DOI: 10.1016/j.humpath.2006.04.008.
[3] ANKIT B M D, AFT R L, FENG G, et al. Patient and tumor characteristics associated with increased mortality in young women(≤40 years)with breast cancer[J]. Surg Oncol,2009,100:248-251.
[4] HOHENBERGER P, GRETSCHEL S. Gastric cancer[J]. Lancet, 2003,362(9380):305-315.
[5] HU B S, YU H F, ZHAO G, et al.High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma[J]. Int J Clin Exp Pathol,2012,5(7): 668-673.
[6] LLOVET J M, BRUIX J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology, 2008, 48(4): 1312-1327. DOI: 10.1002/hep.22506.
[7] NORDENSTEDT H, WHITE D L, EL-SERAG H B. The changing pattern of epidemiology in hepatocellular carcinoma[J]. Digestive and Liver Disease, 2010, 42: S206-S214. DOI: 10.1016/S1590-8658(10)60507-5.
[8] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[9] XIE C Y, FU L, XIE L L, et al. Rsf-1 overexpression serves as a prognostic marker in Human hepatocellular carcinoma[J]. Tumor Biology, 2014, 35(8): 7595-7601. DOI: 10.1007/s13277-014-2008-8.
[10] SIEGEL R. Cancer statistics[J]. CA Cancer J Clin,2012,62(1):10-29.
[11] LIU S L, DONG Q Z, WANG E H. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer[J]. Tumor Biology, 2012, 33(5): 1485-1491. DOI: 10.1007/s13277-012-0399-y.
[12] CHEN T J,HUANG S C,HUANG H Y,et al.Rsf-1HBXAP overexpresssion is associated with gallbladder carcinoma[J].APMIS,2011,119:808-814.
[13] 郝凤霞.Rsf-1在肺癌中的表达及其对肺癌迁移侵袭能力的影响[D].沈阳:中国医科大学,2014:1-40.
[14] 张秀伟, 谢玲玲, 郝凤霞, 等. Rsf-1在非小细胞肺癌中的表达及意义[J]. 现代肿瘤医学, 2014,22(11): 2597-2599. DOI: 10.3969/j.issn.1672-4992.2014.11.23.
[15] CHOI J H, SHEU J C, GUAN B, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1(HBXAP)as a gene involved in paclitaxel resistance in ovarian cancer[J]. Cancer Research, 2009, 69(4):1407.
[16] 王翔宇. Rsf-1/HBXAP基因在宫颈癌中的作用机制及对放化疗敏感性影响的研究[D]. 济南:济南大学, 2017.
[17] GUIGAY J. Advances in nasopharyngeal carcinoma[J]. Current Opinion in Oncology, 2008, 20(3): 264-269. DOI: 10.1097/cco.0b013e3282fad846.
[18] LEE A W, SZE W M, AU J S, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience[J]. International Journal of Radiation Oncology, Biology, Physics, 2005, 61(4): 1107-1116. DOI: 10.1016/j.ijrobp.2004.07.702.
[19] TAI HUICHUN,HUANG HSUANYING.Association of Rsf-1 overexpression with poor therapeutic response and worse survival in patients with nasopharyngeal carcinoma[J].Clin Pathol,2012,65:248-253.
[20] YAQINUDDIN A, QURESHI SA, PERVEZ S, et al. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin[J]. ISRN Urol,2013,2013:627249
[21] BANERJEE P, AMIN K. The cellular functions of RASSF1A and its inactivation in prostate cancer[J]. Journal of Carcinogenesis, 2012, 11(1): 3-T. DOI: 10.4103/1477-3163.93000.
[22] LI H, ZHANG Y, ZHANG Y, et al. Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker[J]. Tumor Biology, 2008, 35(6):5771-5776.DOI: 10.1007/s13277-014-1766-7.
[23] CHAN J K, TEOH D, HU J M, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers[J]. Gynecol Oncol, 2008,109:370-376.
[24] USHIJIMA K. Current status of gynecologic cancer in Japan[J]. J Gynecol Oncol,2009,20:67-71.
[25] VERAS E, MAO T L, AYHAN A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases[J]. The American Journal of Surgical Pathology, 2009, 33(6): 844-853. DOI: 10.1097/PAS.0b013e31819c4271.
[26] MAEDA D, CHEN X, GUAN B, et al. Rsf-1(HBXAP)expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma[J]. International Journal of Gynecological Pathology, 2011, 30(1): 30-35. DOI: 10.1097/pgp.0b013e3181e9a319.
[27] MOHAN A, PONNUSANKAR S. Newer therapies for the treatment of metastatic breast cancer: a clinical update[J]. Indian Journal of Pharmaceutical Sciences, 2013, 75(3): 251-261. DOI: 10.4103/0250-474X.117396.
[28] 李梅芳,何建蓉.人类组织激肽释放酶基因与乳腺癌关系的研究进展[J].中华乳腺病杂志(电子版),2010,4:559-563.
[29] IEMING S, JIM J S, ANTONIO S, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma[J]. Proc Natl Acad Sci U S A, 2005, 102(39): 14004-14009.
[30] DAVIDSON B, WANG T L, SHIH I M, et al. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions[J]. Human Pathology, 2008, 39(4): 616-622. DOI: 10.1016/j.humpath.2007.09.008.
[31] DAVIDSON B, REICH R, LAZAROVICI P, et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma[J]. Breast Cancer Research and Treatment, 2004, 83(2): 119-128.DOI: 10.1023/b:brea.0000010704.17479.8a.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	. [J]. Journal of Hebei Medical College for Continuing Education, 2023, 40(1): 1-9.
[2]	QU Penghuan, SHI Jianhong. Advances on Y-box binding protein 1’s functions in the tumorigenesis and oncotherapy [J]. Medical Reserch and Education, 2015, 32(5): 74-77.
[3]	ZHANG Xujia, CHEN Shouying, CUI Lizhou, Hou Ye, MA Jifei. Analysis of malignant tumor burden in Baoding urban residents in 2009 [J]. Medical Reserch and Education, 2014, 31(6): 65-67.